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Donor lymphocyte infusion has been used in the management ofrelapsed hematologic malignancies after allogeneic hematopoieticcell transplantation. It can eradicate minimal residual disease or be
used to rescue a hematologic relapse, being able to induce durable remis-
sions in a subset of patients. With the increased  use of haploidentical
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Introduction
Allogeneic hematopoietic cell transplantation (allo-
HCT) remains an important therapeutic option for a wide
number of both hematologic malignancies and non-
hematologic disorders. With improvements in condition-
ing regimens, graft-versus-host disease (GvHD) prophy-
laxis and supportive care, leading to a reduced risk of
transplant-related mortality, disease relapse has become
the foremost cause of mortality after allo-HCT. The
cumulative incidence of relapse (CIR) after allo-HCT for
acute leukemia can be as high as 40-50% with only 10-
15% long-term survival in patients experiencing leukemia
recurrence.1-3 Strategies aimed at preventing and/or treat-
ing disease relapse have the greatest potential to improve
transplant outcomes. Donor-lymphocyte infusion (DLI)
has an established role in the management of disease
relapse after allo-HCT. Unmanipulated DLI is a form of
immunotherapy, which can induce durable remissions by
enhancing the graft-versus-tumor (GvT) effect.4-6 Efficacy
of DLI varies by type and burden of the disease.7 DLI is
more effective in chronic myeloid leukemia (CML), lead-
ing to complete remission (CR) in 70-80% of patients in
hematologic or cytogenetic CML relapse, whereas less
than 40% of acute leukemia patients respond to DLI.8,9 A
study by Schmid et al. using the European Society for
Blood and Marrow Transplantation (EBMT) registry
showed DLI was associated with improved survival of
patients with AML in the first hematologic relapse after
allo-HCT, but 2-year overall survival (OS) was only 15%
if DLI was given in the setting of active disease.10 Pre-
emptive DLI for mixed chimerism or molecular disease
relapse and prophylactic DLI for high-risk hematologic
malignancies have also been studied with promising
results in the setting of human leukocyte antigen (HLA)-
matched allo-HCT.11-13
Allo-HCT from an HLA-haploidentical related donor
(haplo-HCT) has emerged as a suitable alternative for
those patients who need an allograft but who lack an
HLA-matched related or unrelated donor.14,15 Several T-
cell depleted and T-cell replete haploidentical transplant
strategies are applied today. In T-cell replete haploidenti-
cal stem cell transplantation, the use of post-transplant
cyclophosphamide (PTCy) has rapidly increased across
the globe due to its logistical simplicity and efficacy.2
Another T-cell replete haplo-HCT platform is granulocyte
colony stimulating factor (GCSF)-antithymocyte globulin
(ATG)-based or “GIAC” protocol’ [GCSF-stimulation of
the donor; intensified immunosuppression through post-
transplantation cyclosporine (CSA), mycophenolate
mofetil (MMF), and short-course methotrexate (MTX);
anti-thymocyte globulin (ATG); and combination of
peripheral blood stem cells (PBSC) and bone marrow
(BM) allografts] initially developed at the Peking
University.16 Today’s T-cell depleted strategies derive
from the mega-dose CD34+ protocol developed at the
Perugia University17 and represent a historical standard in
T-cell depletion. From this platform, several other T-cell
depleted strategies have evolved, such as CD3/CD19 cell
depletion18 and α-β-T/CD19-B cell depletion.19 The adop-
tive transfer of selectively allo-depleted20 or gene-modi-
fied T cells with a suicide switch21,22 after T-cell depleted
transplantation  have further optimized this transplant
form and are now being investigated in large randomized
trials in comparison with PTCy.
Haplo-HCT with PTCy has shown comparable clinical
outcomes to matched unrelated donor allo-HCT in retro-
spective analyses with a significantly lower risk of
chronic GvHD in myeloid and lymphoid malignancies,
regardless of whether the graft was obtained from BM or
mobilized PBSC.23-26 There is concern that DLI from a
haploidentical donor (haplo-DLI) may pose an increased
risk for GvHD, given the higher degree of HLA disparity
between the donor and recipient. However, a greater
HLA-disparity may also be beneficial in promoting a
stronger GvT effect.27 Another advantage is that a related
haploidentical donor is, in most cases, readily available
and collection is faster than a registry-based unrelated
donor. While the experience with haplo-DLI is limited,
and there are many uncertainties around its clinical appli-
cation, it can be a powerful tool to manage a disease
relapse after haplo-HCT. Nonetheless, it should be
emphasized that haplo-DLI after T-cell depleted trans-
plantation without full immune reconstitution may have
very different effects than after T-cell replete transplanta-
tion and may require completely different dosing strate-
gies. Therefore,  in the absence of data from prospective
clinical trials, general recommendations cannot be made. 
In this review, we summarize the published experience
with haplo-DLI and provide recommendations regarding
its use in various clinical settings (therapeutic vs. pre-
emptive vs. prophylactic DLI), use of chemotherapy
before DLI, optimal cell dose, and concurrent immuno-
suppression management. Newer strategies using cellu-
lar engineering, donor-derived natural killer (NK) cells
and pharmacological immunomodulation are also dis-
cussed.
Therapeutic haplo-donor-lymphocyte infusion:
hematologic relapse
Previously published retrospective studies have sug-
gested that outcomes of haplo-DLI in patients with
hematologic relapse are comparable to standard DLI from
an HLA-matched donor. The incidence of DLI-associated
GvHD also appears to be similar regardless of donor
type.28-30 Possible explanations, at least when used late
post transplant, are the use of lower cell dose and pres-
ence of donor-derived tolerogenic cells in the recipient,
hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat
or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown
encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation
platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European
Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor
lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emp-
tive and prophylactic use in clinical practice.
which may reduce their alloreactivity and, thus, the risk
of GvHD. The type of haplo-HCT protocol may influ-
ence outcomes of subsequent haplo-DLI. The current
therapeutic haplo-DLI experience is limited to haplo-
HCT/PTCy or a ‘GCSF-ATG-based protocol’. Table 1
summarizes the published studies using DLI from a hap-
loidentical donor.
Therapeutic donor-lymphocyte infusion in T-cell
replete haplo-hematopoietic cell
transplantation
Zeidan et al. retrospectively reported results of haplo-
DLI in 40 patients [minimal residual disease (MRD)/loss
of chimerism (LOC): n=5; hematologic relapse: n=35]
after a haplo-HCT/PTCy with BM graft. At the median
follow up of seven months, CR was achieved in 30% of
patients (CR after a hematologic relapse: 26%) and acute
GvHD (aGvHD) occurred in 25% of them. At time of  last
follow up, six patients were alive in CR for over a year
after the intervention. The cell dose in most DLI was
1x106 CD3+ cells/kg and the majority of patients received
cytoreductive chemotherapy before DLI.28 Subsequently,
two similar reports showed that haplo-DLI after
chemotherapy successfully resulted in CR in approxi-
mately 30% of the patients with a subset of long-term
survivors.29,30 The incidence of grade 2-4 aGvHD was
approximately 30%, and only 5% of patients developed
grade 3-4 aGvHD. No patient (0%) developed extensive
chronic GvHD (cGvHD).29,30 None of these studies used
immunosuppression for GvHD prophylaxis after haplo-
DLI. Disease responses and GvHD rates were comparable
between patients who received BM versus a PBSC graft.30
Patients with relapsed Hodgkin lymphoma appear to
have relatively better disease responses to haplo-DLI
compared to those with acute leukemia (40% vs. 33%).29
In a smaller retrospective study (n=21) published by
Goldsmith et al., the authors showed that patients with
extra-medullary disease relapse had a better relapse-free
survival (RFS) compared to those with marrow relapse (4-
month RFS 43% vs. 8%).30 The group at Peking University
has developed a haplo-DLI protocol using GCSF-primed
peripheral blood progenitor cells (GBPC) with short-term
immunosuppression. They have used a higher cell dose
(1x107 to 1x108 CD3+ cells/kg) than that used in haplo-DLI
in the setting of allo-HCT/PTCy (1x105 to 1x106 CD3+
cells/kg).31-37 An earlier prospective study using GBPC
without immunosuppression resulted in a high incidence
of severe GvHD (grade 3-4 aGvHD 30%, extensive
cGvHD 30%), resulting in 2-year disease-free survival
(DFS) of 40% and non-relapse mortality (NRM) of 25%.38
Subsequent studies used cytoreductive chemotherapy
before GBPC infusion (chemo-DLI) followed by GvHD
prophylaxis with low-dose weekly MTX or CSA for 6-8
weeks. A retrospective report by Yan et al. on 55 patients
with relapsed acute leukemia showed 3-year DFS, NRM,
and OS of 24%,13%, and 25%, respectively. A total of
76% of patients achieved CR (MRD negative CR: 55%).39
Relapse after achieving CR following chemo-DLI was a
major problem, resulting in poor long-term survival. In
spite of the limitations of cross-study comparison, out-
comes of chemo-GBPC infusion with short-course
immunosuppression are comparable to unmanipulated
haplo-DLI after haplo-HCT/PTCy.
Pre-emptive haplo-donor-lymphocyte infusion:
minimal residual disease, mixed-donor
chimerism
Impact of minimal residual disease and mixed-
chimerism on haplo-hematopoietic cell transplantation
outcomes
Strategies are being explored to reliably predict the risk
of disease relapse after an allo-HCT in the hope of imple-
menting pre-emptive treatments. The presence of MRD
before or after allo-HCT is associated with significantly
increased risk of relapse and reduced survival in both
acute lymphoblastic leukemia (ALL) and acute myeloid
leukemia (AML).40,41 Canaani et al. looked at pre-haplo-
HCT MRD positivity in AML patients and showed its
negative correlation with leukemia-free survival.42 Low
donor T-cell chimerism [mixed-chimerism (MC)] after an
allo-HCT is also associated with poor donor-derived
immune reconstitution and increased risk of disease
relapse, especially after myeloablative conditioning. In
patients with AML/MDS who underwent myeloablative
allo-HCT, donor T-cell chimerism <85% at day (d)+90
and d+120 was associated with increased risk of 3-year
disease progression (HR=2.1, P=0.04).43 Koreth et al.
reported that d+100 total donor chimerism <90% was
associated with increased risk of relapse (HR= 2.54,
P<0.001) and lower OS (HR=1.50, P=0.009) in patients
after a reduced-intensity allo-HCT.44 Pre-emptive DLI
from a full matched donor for MRD and MC appears to
be safe and effective in improving disease-specific out-
comes.45,46
Pre-emptive donor-lymphocyte infusion in T-cell replete
haplo-hematopoietic cell transplantation
In the previously mentioned retrospective study by
Zeidan et al., 3 of 4 patients who received haplo-DLI for
MRD entered CR.28 Similarly, other reports showed high-
er response rates in patients who received haplo-DLI for
MRD or MC compared to the administration at the time
of hematologic relapse.29,30 Yan et al. reported comparative
outcomes of prospective studies of standard-risk acute
leukemia and MDS patients with persistent MRD after
allo-HCT (haploidentical donor, n=29; matched donor,
n=27), who received low-dose interleukin-2 (IL-2) or pre-
emptive DLI. The latter was associated with reduced 3-
year CIR compared to IL-2 alone (28% vs. 64%;
P=0.001).31 In another retrospective study by Mo et al.,
101 patients (haplo-HCT, n=56) received chemo-DLI for
persistent MRD after an allo-HCT. Three-year CIR,
NRM, and OS were 40%, 10%, and 52%, respectively.
Patients who cleared their MRD within 30 days after pre-
emptive chemo-DLI had lower relapse rates compared to
those with persistent MRD beyond 30 days (20% vs.
47%; P=0.001).36 It should be noted that the published
data on pre-emptive haplo-DLI for MC is limited to a few
patients28,30 and further studies are needed to establish its
role in preventing disease relapse. 
It is important to monitor for MRD after allo-HCT as
DLI is probably more effective when administered for
MRD only compared overt hematologic relapse.47
Retrospective studies have shown that persistent MRD
post-transplant is associated with high relapse rate and
poor outcomes,48 and the eradication of MRD improves
survival.46 Comparative studies are needed between DLI
and other systemic therapies in order to develop disease-
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Table 1. Donor-lymphocyte infusion from a haploidentical donor.
Study                  N. of patients        Diagnosis         Indication      Treatments         CD3+                  N. of DLI     Disease              Rate of                 Survival                 Notes
                          (prospective/                                  for DLI         before DLI      dose/kg     (median)    response             GvHD
                          retrospective)                                        
T-cell depleted 
haplo-HCT                                                                                                                                                                                                                                           
Lewalle et al.                   12                        AML=5       Prophylactic=12       None               1-4x104                                                                   58%                 1-yr RFS=50%,            T-/B-cell 
(2003)65                   (prospective)             ALL=3                                                                                                                                                                                1-yr OS=50%,       depleted graft 
                                                                        CML=1                                                                                                                                                                                   NRM=0%
                                                                       Other=3                     
Dodero et al.                    23                    Lymphoma     Prophylactic-23        None              2-15x104                          2                   NA                aGvHD=26%          2-yr PFS=45%          CD8+ T-cell 
(2009)62                   (prospective)                CLL                                                                                                                                             (grade 3-4=9%)        2-yr OS=44%         depleted DLI
                                                                           ALL                                                                                                                                                 cGvHD=15%             NRM=26%
                                                                           MM                                                                                                                                            (extensive=12%)
                                                                           AML
Martelli et al.                   43                      AML=33       Prophylactic-43        None      Treg=2.5x106±1.1        1                   NA                      aGvHD               CI NRM=40%         Treg on day-4,
(2014)61                               (prospective)            ALL=10                                                             Tcon=1.1x106±0.6                                               (grade ≥2)=15%       46-m relapse          Tcon on day 0
                                                                                                                                                                                                                                   cGvHD=16%                  =5%
                                                                                                                                                                                                                                (extensive=7%)
Gilman et al.                    34                 AML/MDS=13  Prophylactic-34        None               3-5x104                 1                   NA                      aGvHD                2-yr OS=63%       Post-DLI-GvHD
(2018)60                   (prospective)            ALL=10                                                                                                                                          (grade 3-4)=4%      2-yr NRM=25%          ppx=100%
                                                                      Other=11                                                                                                                                           cGvHD=16% 
                                                                                                                                                                                                                                (extensive=7%)
T-cell replete 
haplo-HCT
Or et al.                            28                       AML=12        Prophylactic-6         None        1x102 to 15x108    1-7 (1)        CR=18%                   46%                     NRM=11%                       
(2006)106            (haplo-26,MMUD-2)       ALL=7        Therapeutic- 22             
                                (retrospective)           CML=5
                                                                       Other=3                     
Huang et al.                      20                        AML=7        Therapeutic=20       CT=9         0.07-4.39x108      1-3 (1)        CR=75%           aGvHD=55%          2-yr DFS=40%      Post-DLI-GvHD
(2007)38*                (prospective)            ALL=10                                            TKI=2                                                                                 (grade 3-4=30%)         NRM=25%               ppx=55%
                                                                        CML=3                                                                                                                                             cGvHD=64% 
                                                                                                                                                                                                                               (extensive=30%)
Yan et al.                           56                      AML=32      Pre-emptive=56      CT=32           0.75-2x108              1                   NA                aGvHD=31%          3-yr DFS=56%      Post-DLI-GvHD
(2012)31*           (haplo-29, matched      ALL=21               (MRD)                                                                                                             (grade 3-4=8%)        3-yr OS=58%           ppx=100%
                            related-26, MUD-1)       MDS=3                                                                                                                                             cGvHD=43%         3-yr NRM=14%
                                 (prospective)                                                                                                                                                                   (extensive=34%)
Yan et al.                          124                     AML=49      Prophylactic=74      CT=27        0.13-2.11x108       1-4(1)              NA                aGvHD=53%          2-yr CIR=35%      Post-DLI-GvHD
(2012)69*               (retrospective)          ALL=59          Therapeutic/        (MRD+)                                                                               (grade 3-4=28%)       2-yr OS=47%           ppx=100%
                                                                        MDS=5         pre-emptive=   All relapsed                                                                                                                2-yr NRM=34%
                                                                       CML=11             50(MRD)    pts received CT.                                                                                                         In disease relapse,
                                                                                                                                                                                                                                                                     2-yr CIR=45%
                                                                                                                                                                                                                                                                      2-yr OS=19%
                                                                                                                                                                                                                                                                    2-yr NRM=37%
Wang et al.                        61                      AML=42      Prophylactic=61      CT=0%          0.9-7.2x108              1                   NA                aGvHD=48%          3-yr DFS=22%      Post-DLI-GvHD
(2012)66*               (retrospective)          ALL=19                                                                                                                                         (grade 3-4=10%)       3-yr OS=31%           ppx=100%
                                                                                                                                                                                                                                   cGvHD=39%         2-yr NRM=38%
                                                                                                                                                                                                                               (extensive=31%)                  
Yan et al.                           50                       AML=29       Therapeutic=50    CT=100%      0.11-2.07x108          NA            CR=64%           aGvHD=66%          1-yr DFS=36%      Post-DLI-GvHD
(2013)33*               (retrospective)          ALL=21                                                                                                                                         (grade 3-4=40%)       1-yr OS=36%           ppx=100%
                                                                                                                                                                                                                                   cGvHD=44%         1-yr NRM=14%
                                                                                                                                                                                                                               (extensive=42%)
Yan et al.                           55                      AML=18       Therapeutic=55    CT=100%      0.19-0.74x108          NA            CR=76%           aGvHD=44%          3-yr DFS=24%      Post-DLI-GvHD
(2015)39*               (retrospective)          ALL=23                                                                                                             MRD negative (grade 3-4=11%)       3-yr OS=25%           ppx=100%
                                                                                                                                                                                                        CR=55%           cGvHD=49%         3-yr NRM=13%                   
                                                                                                                                                                                                                               (extensive=42%)
Mo et al.                           101                AML/MDS=69     Pre-emptive       CT=100%        1.7-7.4x107            NA            CR=76%            aGvHD=9%              AML/MDS,         Post-DLI-GvHD 
(2016)36*                  (haplo=58)              ALL=32           =101(MRD)                                                                                                        (grade 3-4=4%)       3-yr DFS=57%          ppx=100%
                                (retrospective)                                                                                                                                                                      cGvHD=59%                   3-yr
                                                                                                                                                                                                                                                                         NRM=7%
                                                                                                                                                                                                                                                                ALL, 3-yr DFS=49%
                                                                                                                                                                                                                                                                              3-yr
                                                                                                                                                                                                                                                                        NRM=11%                       
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Yan et al.                           47                      AML=25      Pre-emptive=47    CT=100%        1.5-6.4x107            1-4                 NA                aGvHD =19%         1-yr DFS=71%      Post-DLI-GvHD
(2016)57*#                 (haplo=31)              ALL=22               (MRD)                                                                                                             (grade 3-4=6%)                1-yr                    ppx=100%
                                 (prospective)                                                                                                                                                                        cGvHD=79%              NRM=9%
                                                                                                                                                                                                                             (≥moderate=66%)             1-yr
                                                                                                                                                                                                                                                                          OS=78%
Yan et al.                          100                     AML=59     Prophylactic=100     CT=0%          1.8-6.6x107            NA                 NA                  Haplo-HCT,              Haplo-HCT,         Post-DLI-GvHD
(2017)32*                  (haplo=62)              ALL=41                                                                                                                                             aGvHD =47%         3-yr DFS=51%          ppx=100%
                                 (prospective)                                                                                                                                                                   (grade 3-4=10%)               3-yr
                                                                                                                                                                                                                                   cGvHD=63%             NRM=18%
                                                                                                                                                                                                                             (≥moderate=59%)             3-yr
                                                                                                                                                                                                                                                                          OS=49%                         
Ma et al.                            36                     AML/ALL/      Therapeutic=36      CT/TKI                 NA                   NA            CR=56%              Grade 3-4            3-yr DFS=11%      Post-DLI-GvHD
(2017)34*               (retrospective)        MDS/CML                                         =100%                                                                                    aGvHD=25%)                  3-yr                    ppx=100%
                                                                                                                                                                                                                                      Extensive                 OS=14%
                                                                                                                                                                                                                                   cGvHD=36%
Gao et al.                          31                      AML=21      Prophylactic=31      CT=0%          0.4-6.9x107              1                   NA                aGvHD=58%          2-yr RFS=32%      Post-DLI-GvHD 
(2018)54*               (retrospective)           ALL=5                                                                                                                                           (Grade 3-4=7%)     2-yr NRM=33%          ppx=100%
                                                                        CML=2                                                                                                                                              cGvHD=39%                   2-yr
                                                                       Other=3                                                                                                                                     (Mod-severe=29%)       OS=40%                         
Zeidan et al.                     40                      AML=16       Therapeutic=35     CT/RT=              1x105             1-4(1)        CR=30%           aGvHD=25%        8/12 responders
(2014)28+                         (retrospective)           ALL=3         Pre-emptive=5          70%               to 1x108                                              (MRD=75%,   (grade 3-4=15%)        (67%) alive,
                                                                        CML=1          (MRD+/MC)                                                                          Relapse=26%)      cGvHD=8%                 in CR at 
                                                                 Lymphoma=11                                                                                                                                  (extensive=5%)        17.5 months
                                                                       Other=9                                                 
Ghiso et al.                       42                       AML=22       Therapeutic=22     CT/RT=              1x103                1-6            CR=36%           aGvHD=33%      Leukemia, median
(2015)29+                         (retrospective)           ALL=9        Pre-emptive=20        100%              to 1x107          (mean-2.5)  CR in MRD      (grade 3-4=5%) response=4m(2-10),
                                                                         HL=10                (MRD)                                                                                        =45%               cGvHD=0%         median survival
                                                                                                                                                                                                                                                                        =7m(1-15)
                                                                         MM=1                                                                                                                                                                         HL, median response
                                                                                                                                                                                                                                                                       =9m(3-28),
                                                                                                                                                                                                                                                                   median survival
                                                                                                                                                                                                                                                                       =18m(4-34)                      
Jaiswal et al.                     21                      AML=21      Prophylactic=21      CT=0%         9.2-110x107           1-3                 NA                Cum incident       1.5-yr PFS=62%    Post-DLI-GvHD 
(2016)56$                  (prospective)                                                                                                                                                                       aGvHD =31%                 1.5-yr                   ppx=100%
                                                                                                                                                                                                                                   cGvHD=41%              CIR=21%
                                                                                                                                                                                                                                                                             1.5-yr
                                                                                                                                                                                                                                                                          OS=71%                         
Goldsmith et al.              21                 AML/MDS=16  Therapeutic=19     CT=76%         0.01-3x107            1-5            CR=32%           aGvHD=33%           Hematologic      PBSC haplo-HCT
(2017)30+                         (retrospective)           ALL=2    Pre-emptive=2(MC)                                                                                                (grade 3-4=5%)            relapse,
                                                                        CML=2                                                                                                                                             cGvHD=26%           4-m RFS=8%
                                                                 Lymphoma=11                                                                                                                                   (extensive=0%)       4-m OS=29%
                                                                       Other=9                                                                                                                                                                               EM relapse,
                                                                                                                                                                                                                                                                     4-m RFS=43%
                                                                                                                                                                                                                                                                      4-m OS=71%                     
Cauchois et al.                 36                 AML/MDS=25 Prophylactic=36      CT=0%          0.1-2.5x106            1-3                 NA        1-yr CI of mod-severe 1-yr PFS=83%       PBSC graft=31
(2018)67+                         (retrospective)           ALL=2                                                                                                                                               GvHD=33%           1-yr NRM=9%
                                                                  Lymphoma=6                                                                                                                                                                                   1-yr
                                                                       Other=3                                                                                                                                                                                   OS=76%                         
N: number; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodyslastic syndromes; MMUD: mismatched unrelated donor; GvHD ppx:
graft-versus-host disease prophylaxis;  aGvHD: acute GvHD; cGvHD: chronic GvHD; OS: overall survival;  DFS: disease-free survival;  PFS: progression-free survival;  NRM: non-relapse mortality;  CT:
chemotherapy;  TKI: tyrosine kinase inhibitor;  MRD: minimal residual disease;  MC: mixed-chimerism;  NA: not available;  RT: radiation therapy;  PBSC: peripheral blood stem cell;  EM: extra-medullary
relapse; RFS: relapse-free survival;  haplo-HCT: haploidentical-hematopoietic cell transplant;  matched: HLA-matched allo-HCT;  MUD: HLA-matched unrelated donor;  Treg: regulatory T-cell;  Tcon: con-
ventional T-cells;  CI: cumulative incidence; yr: year; m: months; NA: not available. *Granulocyte colony-stimulating factor (GCSF)-anti-thymocyte globulin (ATG)-based protocol and G-CSF-primed
peripheral blood progenitor cell (GBPC). $Haplo-HCT with post-transplant cyclophosphamide (PTCy) and GBPC. +Haplo-HCT with PTCy and standard donor-lymphocyte infusion (DLI). #Patients
had salvage chemotherapy + therapeutic DLI for hematologic relapse, followed by pre-emptive DLI for persistent minimal residual disease (MRD). pt: patient; mod: moderate; cum: cumulative; HL:
Hodgkin lymphoma.
Study                    N of patients       Diagnosis        Indication      Treatments         CD3+                   N. of DLI     Disease              Rate of                 Survival                 Notes
                            (prospective/                                 for DLI         before DLI      dose/kg     (median)    response             GvHD
                            retrospective)                                      
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specific MRD management strategies. DLI should not be
used in patients who have converted to host chimerism
due to increased risk of marrow aplasia.49 An alternative
strategy for such patients would be to undergo a second
allo-HCT from the same or from a different donor. It is
important to weigh the risk of GvHD and marrow aplasia
versus the potential benefit of reducing the disease relapse
when considering pre-emptive DLI for MRD or MC.
Prophylactic haplo-donor-lymphocyte infusion 
Prophylactic DLI from a matched donor has been stud-
ied in patients with high-risk myeloid malignancies and
was associated with improved disease-specific outcomes
and low NRM.11,50,51 It can contribute to immune reconsti-
tution and reduce the risk of infection,52 which is a major
challenge after a T-cell depleted haplo-HCT. A matched-
pair analysis by the EBMT showed improved OS in high-
risk AML recipients who received prophylactic DLI from
a matched donor (70% vs. 40% in controls; P=0.027).53
Inclusion criteria differ among published studies in their
definition of high-risk disease. Most reports included
patients with primary induction failure acute leukemia,
high disease risk index, active disease before allo-HCT or
the presence of high-risk mutations (i.e. TP53, ASXL1,
RUNX1) in myeloid malignancies.54-57 One of the first
experiences with prophylactic haplo-DLI was in the set-
ting of autologous-HCT. Nagler et al. reported outcomes
of 26 patients who received multiple haplo-DLI
(with/without IL-2) after an autologous-HCT. This
approach was feasible in inducing GvHD, but higher cell
doses led to increased toxicity.58 The timing of prophylac-
tic-DLI is also important as decreasing the interval
between allo-HCT and DLI will likely increase the risk of
aGvHD.13 The activity of ATG, given as a part of condi-
tioning, may persist for weeks, and residual ATG may
negatively impact prophylactically infused donor lym-
phocytes.59 At the same time, the administration of haplo-
DLI as early as d+45 was feasible in single center stud-
ies.32,56 It may be reasonable to administer prophylactic
haplo-DLI before d+90 given that median time to relapse
after allo-HCT is approximately three months.
Prophylactic donor-lymphocyte infusion in T-cell 
depleted haplo-hematopoietic cell transplantation
Early experience with prophylactic haplo-DLI was with
T-cell-depleted haplo-HCT where donor lymphocytes
were infused after a CD34+ cell-selected graft to enhance
immune reconstitution.60-62 Perruccio et al. showed that
infusion of donor-derived non-alloreactive T cells specific
for cytomegalovirus (CMV) and aspergillus resulted in the
rapid development of T-cell responses against these
pathogens without inducing GvHD.63 Another prospec-
tive study utilized CD8+ T-cell depleted DLI, which
resulted in aGvHD in 26% of patients with 2-year PFS of
45%.62 Donor-derived T regulatory cells (Tregs), co-infused
with conventional T cells (Tcons) were shown to protect
recipients against GvHD.64 In a prospective study,
patients received Tregs (d -4) followed by a megadose of
CD34+cells and Tcons on d0 from a haploidentical donor
without any post-transplant immunosuppression. Only
15% of the patients developed ≥grade 2 aGvHD and DFS
was 56% at 18 months.61 In another prospective study by
Gilman et al., 34 pediatric patients were infused an unma-
nipulated prophylactic haplo-DLI with MTX between
d+30 and d+42 after a T-cell depleted/CD34+ selected
haplo-HCT. The intervention was safe and 2-year NRM
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Figure 1. Proposed treatment algorithm of therapeutic, pre-emptive and prophylactic donor-lymphocyte infusion (DLI) following T-cell replete haploidentical
hematopoietic cell transplantation (HCT). HLA: human leukocyte antigen; MRD: minimal residual disease; GvHD:  graft-versus-host disease; TKI: tyrosine kinase
inhibitor.
and OS were 25% and 63%, respectively.60 Lewalle et al.
reported the outcomes of 12 patients who received pro-
phylactic haplo-DLI starting on d+28 after T-/B-cell
depleted haplo-HCT in a prospective study. One-year
RFS, NRM, and OS were 50%, 0%, and 50%, respective-
ly.65 Despite the encouraging results with prophylactic
infusion of T-cell subset after a T-cell deplete/CD34+
selected haplo-HCT, its widespread adoption has been
challenging as cell selection remains a labor-intensive and
expensive process.
Prophylactic donor-lymphocyte infusion in T-cell replete
haplo-hematopoietic cell transplantation
The Chinese group has led the way by incorporating
prophylactic GBPC in high-risk malignancies after a
haplo-HCT with the GCSF-ATG-based protocol. In a ret-
rospective study by Wang et al., 61 patients with high-risk
leukemia who underwent GBPC infusion were compared
to 27 patients who received routine care after an haplo-
HCT. Prophylactic GBPC was associated with lower
relapse rate (36% vs. 55%; P=0.017) and superior estimat-
ed 3-year survival (31% vs.  11%; P=0.001) compared to
routine care. There was no difference in NRM between
the two groups.66 A prospective study by the same group
enrolled 62 patients with high-risk acute leukemia. All
patients received prophylactic GPBC between d+45 and
d+60 and further DLI were guided by MRD and GvHD
status. Three-year DFS, NRM, and OS were 51%, 18%,
and 49%, respectively. Acute and chronic GvHD were
seen in 47% and 63% patients, respectively. Outcomes
were similar between recipients of haploidentical (n=62)
versus matched donor (n=38) prophylactic DLI.32
Jaiswal et al. reported their prospective experience with
prophylactic GBPC in the T-cell replete haplo-HCT/PTCy
setting. Twenty-one patients with AML (not in remission)
received up to three doses of haplo-GPBC (d+21, d+35
and d+60). They were compared with 20 patients who
received routine monitoring after haplo-HCT. At 18
months, CIR, PFS, and OS were 21% versus 66%; 62%
versus 25% and 71% versus 35% in DLI and routine care
cohorts, respectively. Incidence of aGvHD was 31%,
while incidence of chronic GvHD was 41% after GBPC
infusions. NRM was equivalent between the groups.56
Recently, Cauchios et al. reported outcomes of 36 patients
who received prophylactic haplo-DLI after a haplo-
HCT/PTCy. One-year PFS and OS were 76% and 83%,
respectively. The cumulative incidence of relapse was
16% and the incidence of DLI-associated GvHD was
33%.67
Practical aspects of haplo-donor-lymphocyte
infusion
Cell dose
The CD3+ T-cell dose ranged from 0.01 to 8.8x108
mononuclear cells/kg in reports on therapeutic DLI from
a matched donor.7 A study reported a relatively lower rate
of GvHD with an escalating cell dose regimen versus a sin-
gle bulk infusion of DLI from HLA-matched donors.
Disease responses were similar between the two
approaches.68 There was no dose-response relationship
with GvHD or disease response rates in haplo-DLI in the
setting of T-cell depleted haplo-HCT.28,29 The average
starting dose for therapeutic haplo-DLI in the T-cell
replete haplo-HCT/PTCy setting was 1 or 2 log lower
than the standard DLI dose (1x107 CD3+ cells/kg) from
HLA-matched donors. In a report on 40 patients, a cell
dose of 1x106 CD3+ cells/kg was associated with grade 2-
4 aGvHD in 17% of patients, and a CR rate of 27%.28
Goldsmith et al. used the same dose in 21 patients; only
seven (33%) developed aGvHD (grade 3-4 aGvHD in 1
patient).30 These incidences of aGvHD were lower than
those reported by the Chinese group using haplo-GBPC
at 1 to 2 log higher cell dose with the GCSF-ATG-based
protocol. A starting cell dose of 1x107 to 1x108 CD3+
cells/kg was associated with grade 2-4 aGvHD in 50-60%
(grade 3-4 aGvHD approximately 30%) of patients.31,38,69
Subsequent reports by Yan et al. showed a reduced inci-
dence of aGvHD with the routine use of short-term
GvHD prophylaxis after GBPC infusion.39 Available data
suggest that 1x106 CD3+cells/kg is a reasonable starting
dose with appropriate repeated dose escalation every 4-6
weeks based on disease response and GvHD for thera-
peutic haplo-DLI in T-replete haplo-HCT with PTCy.
Clinical trials are needed to establish the optimal timing
and cell dose in prophylactic and T-cell depleted haplo-
HCT settings. Published studies have used wide-ranging
repeated non-escalating cell doses for pre-emptive or pro-
phylactic DLI.32,37,54
The end point of donor-lymphocyte infusion therapy
It is important to establish the goal of DLI therapy
beforehand as each DLI is associated with increased risk
of GvHD. Patients with DLI-responsive relapse usually
respond within 2-3 months.7 Repeated infusions of esca-
lating doses of therapeutic DLI can be administered until
CR is achieved (ideally an MRD-negative status) or the
patient develops clinically significant GvHD. Patients
should be evaluated for GvHD, donor chimerism and dis-
ease response after each DLI. Pre-emptive DLI for MRD
persistence after allo-HCT may be stopped once the
achievement of MRD negativity, significant GvHD or a
hematologic relapse occurs. Donor chimerism should be
assessed after each pre-emptive DLI for MC. Pre-emptive
DLI may be stopped once ≥90% donor chimerism is
achieved. As noted above, DLI can result in marrow apla-
sia in those patients who have converted to host
chimerism. There is no standard duration of prophylactic
DLI outside a clinical trial. In these circumstances, each
dose of prophylactic haplo-DLI should be used with cau-
tion, balancing the risk of disease relapse and GvHD.
Traditional donor-lymphocyte infusion versus
granulocyte colony-stimulating factor-primed 
peripheral blood progenitor cell infusion
Standard DLI uses freshly collected unmanipulated
donor lymphocytes. This approach privileges tumor
alloreactivity over the risk of GvHD. GCSF promotes T-
cell hypo-responsiveness in marrow grafts by increasing
the number of plasmacytoid dendritic cells and mono-
cytes. It also reduces the expression of co-stimulatory
CD28/B7 on monocytes, B and T cells,70 promotes
macrophage71 and T-cell polarization in the BM graft
towards the more tolerogenic pattern. This property is
maintained even after in vitro mixture of G-CSF primed
BM and PBSC grafts.72,73 The Chinese group has reported
their extensive experience with using GBPC instead of
unmanipulated DLI. Huang et al. reported the outcomes
of 20 patients who received therapeutic GBPC from hap-
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loidentical donors (the majority of whom received sal-
vage therapy prior to GBPC infusion); CR was achieved
in 75% of patients and the rates of acute and chronic
GvHD were 55% and 64%, respectively.38 In another
study of pre-emptive GBPC infusion for MRD after an
allo-HCT (haploidentical related donor: n=29; matched-
related donor: n=26), the incidences of acute and chronic
GvHD were 31% and 43%, respectively. Routine
debulking chemotherapy and short-term immunosup-
pression were used in most studies using GBPC.31 A
prospective observational study by Jaiswal et al. used
prophylactic-GBPC in the setting of T-cell replete haplo-
HCT/PTCy.56 The incidence of aGvHD was comparable
but cGvHD was higher than that  reported with unma-
nipulated haplo-DLI in the PTCy setting.28-30 A recent
report from Mexico showed that administration of G-
CSF-primed whole blood units (median cell count
6.7x106 CD3+ cells/kg) from haploidentical donors is safe,
with disease responses and improvement in MC in a
subset of patients.74 Whole blood units can potentially
reduce the cost associated with haplo-DLI in developing
countries. Long-term immune tolerance after PTCy may
be enough to overcome the immunological barrier of
haplo-DLI, and GCSF priming may not be required in
this setting. Comparative studies between unmanipulat-
ed DLI versus GBPC in the setting of haplo-HCT/PTCy
are needed.
Role of concurrent immunosuppression
Graft-versus-host disease is the main limiting toxicity of
DLI, and short-term immunosuppression with DLI may
improve the safety of DLI. Yan et al. reported aGvHD in
31% of patients after pre-emptive GBPC infusion for
MRD persistence after T-cell replete haplo-HCT.31 All
patients received CSA or low-dose MTX for 6-8 weeks
after GBPC. There was no difference in acute and chronic
GvHD rates between CSA and MTX. MTX was associat-
ed with lower relapse rate (38% vs. 81%; P=0.029) and
better DFS (52% vs. 16%; P=0.06). Patients who received
MTX had higher absolute lymphocyte count compared to
those who received CSA, which may have contributed to
better GvT effect.39 The same group also showed that
patients receiving GvHD prophylaxis for 6-8 weeks had a
lower cumulative incidence of grade 3-4 aGvHD than
patients receiving prophylaxis for 4-6, 2-4, and <2 weeks
(9%, 14%, 32%, and 50%, respectively; P=0.018).69 In a
retrospective study, Mo et al. used pre-emptive chemo-
DLI for MRD persistence along with routine prophylaxis
with CSA or MTX (haploidentical donor 6-8 weeks;
matched donor 4-6 weeks). The incidence of aGvHD was
only 9% (grade 3-4 aGvHD: 4%) in their cohort of 101
patients.36 It is important to note here that haplo-DLI
without concurrent immunosuppression in the T-cell
replete haplo-HCT/PTCy setting has been reported to
have a similar incidence of GvHD compared to the GCSF-
ATG-based haplo-HCT protocol, which routinely uses
prophylactic immunosuppression with DLI.28 The poten-
tial impairment of the DLI-mediated GvT effect by CSA
or MTX is  a concern when managing a hematologic
relapse. It is reasonable to add short-term MTX after a
pre-emptive or prophylactic haplo-DLI, especially in
patients with a history of GvHD.56 There are no data
available on concurrent immunosuppression with thera-
peutic haplo-DLI in the T-cell replete haplo-HCT/PTCy
setting.
Combination of systemic therapies with 
donor-lymphocyte infusion
Administration of salvage therapy before the infusion
of DLI may improve its efficacy by reducing the tumor
burden and supporting in vivo expansion of infused T
cells. In this regard, chemotherapy helps eliminate regula-
tory donor T cells and create a favorable immunological
environment for DLI by increasing serum levels of IL-7
that favors peripheral expansion of T cells.75 In the retro-
spective study by Zeidan et al., patients who received a
cytoreductive therapy had better CR rates compared to
those who received unmanipulated haplo-DLI without
any preceding therapy (39% vs. 8%).28 This beneficial
effect of pre-DLI chemotherapy was not seen in a similar
report by Goldsmith et al.30
The downside of pre-DLI chemotherapy is tissue injury
and inflammatory cytokine surge which may increase the
risk of GvHD, especially when used closer to the allo-
HCT.76 Intensive chemotherapy after an allo-HCT is poor-
ly tolerated, and infectious complications are common.34,76
Recently, hypomethylating agents (i.e. azacitidine,
decitabine) have been used with DLI for relapsed
AML/MDS. Azacitidine can induce allogeneic CD8+ T-
cell response by enhancing the expression of epigenetical-
ly silenced tumor-associated antigens.77 A combination of
a hypomethylating agent and DLI is safe with no appar-
ent increase in GvHD or infection risk compared to DLI-
alone.78,79 In a prospective study using azacitidine with
DLI for relapsed disease after HLA-matched allo-HCT,
the CR rate was 23% and the 2-year OS was 17%.80
Another retrospective study utilizing decitabine followed
by DLI for relapsed myeloid malignancies showed an
overall response rate of 25% with 2-year OS of 11%.81
Drugs targeting specific molecular anomalies (BCR-ABL1,
FLT3-ITD, IDH1, IDH2) are increasingly being incorporat-
ed in the treatment of disease relapse or as maintenance
therapy after allo-HCT.82,83 These drugs are safer com-
pared to traditional salvage chemotherapy and may pro-
vide benefit when administered in combination with
DLI.84
Immune escape after haplo-hematopoietic cell
transplantation
Recent data have shed light on mechanisms of immune
escape causing disease relapse after haplo-HCT. In haplo-
SCT, HLA haplotype mismatched in the donor/recipient
pair was replaced by a shared parent haplotype (uni-
parental disomy) in 5 of 17 patients with relapsed AML
post-haplo-HCT.85 In a subsequent retrospective analysis
of 69 patients who relapsed after haplo-HCT, mis-
matched-HLA haplotype loss accounted for 33% of the
relapses.86 Based on retrospective studies, a second allo-
HCT using a donor with a different mismatched haplo-
type or a mismatched unrelated donor may induce a bet-
ter GvT effect compared to same donor from the first
haplo-HCT.86,87 At present, there is no standardized
method of detecting loss of mismatched HLA haplotype
in leukemic cells. HLA-allele specific quantitative poly-
merase chain reaction is required to quantify recipient-
and donor-specific alleles to confirm uniparental disomy
in low-burden disease relapse.86,88
Historically speaking, most patients receiving therapeu-
tic DLI relapse and succumb to their disease. Close mon-
itoring of MRD and donor chimerism after a successful
therapeutic haplo-DLI is important to identify the
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patients who are at high-risk of subsequent relapses. Mo
et al. reported that patients with persistent MRD after DLI
had increased relapse risk (P=0.001), resulting in poor DFS
(P=0.004).36 In a prospective study of 47 patients (66%
received haplo-HCT), MRD-guided repeated administra-
tion of pre-emptive chemo-DLI was effective in reducing
the risk of subsequent relapse after achieving initial dis-
ease response. The one-year CIR, DFS, and OS were
22%, 71%, and 78%, respectively (Figure 1).57
Future directions
Donor-derived natural killer cells
Natural killer cells may play a role in tumor alloreactiv-
ity in the setting of mismatched or haploidentical trans-
plant. A recent study showed a marked reduction in
donor-derived NK cells in the recipients of PTCy, leading
to blunting of NK-cell alloreactivity.89 In a pilot study, pro-
phylactic infusion of CD56+/CD3+ cells after haplo-
HCT/PTCy in patients with refractory active disease was
safe and associated with rapid immune reconstitution.55
The same group used prophylactic DLI primed with abat-
acept (CTLA4Ig), which selectively suppresses T-cell
alloreactivity without interfering with NK-cell activation.
Abatacept with DLI was associated with reduced inci-
dence of aGvHD (10% vs. 31%) and improved relapse-
free survival compared to prophylactic DLI alone.90 In a
phase I study by Ciurea et al., donor-derived NK cells
expanded ex vivo were infused prophylactically before
and after haplo-HCT in high-risk myeloid malignancies.
The intervention was safe and associated with improved
NK-cell number and function, lower viral infections, and
low relapse rate when compared to a historical control
group.91 Several methods to enhance NK-cell alloreactivi-
ty, including combination with immunomodulatory
drugs,92 use of cytokine-activated NK cells,93 and selection
of alloreactive single KIR+ NK cells,94 are under investiga-
tion.
Engineered donor-lymphocyte infusion 
Different strategies are being explored to modify DLI
composition and reduce the risk of GvHD while main-
taining antitumor activity. ATIR101© is a haplo-DLI prod-
uct with alloreactive T cells depleted by ex vivo photode-
pletion.20 In a pooled analysis of two prospective trials, 37
patients received prophylactic ATIR101© after T-cell
depleted haplo-HCT. One-year relapse rate, NRM and OS
were 8%, 33% and 58%, respectively. Interestingly,
aGvHD (grade 3-4) and severe cGvHD were seen in 5%
and 0% of the patients, respectively.95 Alloanergized DLI
generated ex vivo was infused on d+35 after a CD34+
selected haplo-HCT in a phase I study. These donor lym-
phocytes with the reduced donor-specific alloreactivity
expanded in vivo and contributed to immune reconstitu-
tion.96 Another strategy is to insert an inducible suicide
gene in donor lymphocytes so that they can be selectively
eliminated to treat DLI-associated GvHD.21,97 A recent
analysis on 100 children with acute leukemia given a
titrated number of donor T cells transduced with the
inducible caspase-9 safety switch after haplo-HSCT
showed an 82% probability of relapse-free survival.98
Chimeric antigen receptor T-cell (CAR-T) therapy has
emerged as a potent form of adoptive cellular therapy.
Two CD19 CAR-T-cell therapies have been approved by
the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for relapsed/refracto-
ry high-grade B-cell lymphoma and B-ALL.99,100
Prophylactic infusion of CD19 CAR-T cells from a hap-
loidentical donor was found to be safe with only mild
aGvHD in one report.101 There are reports of therapeutic
or pre-emptive donor-derived CAR-T-cell infusion with a
small number of patients achieving durable remissions.
CAR-T-cell-associated GvHD appears to be rare and of
mild severity.102 Selective depletion of CD3+ αβ-TCR+ T
cells (thought to be the principal mediators of GvHD) to
enrich DLI with CD3+ γδ-TCR+ T cells and CD3− CD56+
NK cells is also an attractive strategy to reduce the risk of
GvHD while maintaining tumor alloreactivity.103
Maschan et al. infused low-dose (1x105 CD3+cells/kg)
CD45RA-depleted DLI (memory T cell) in 25 patients
after TCR α/β-depleted haplo-HCT. The intervention
was safe and associated with the expansion of
cytomegalovirus-specific T cells in the recipients.52
Donor-lymphocyte infusion with immunomodulatory
drugs
Immunomodulation with checkpoint inhibitors and
targeted agents may enhance the efficacy of DLI. This
may allow lower CD3+ cell dose while maintaining tumor
alloreactivity. Blinatumomab (a CD19-CD3 bispecific T-
cell engager) has been used with DLI for relapsed B-ALL.
In a recent report of 14 patients, it appears to be safe with
high response rates.104 In a prospective phase II study, DLI
was administered with azacitidine and lenalidomide in
patients with molecular or hematologic relapse of
myeloid malignancies. The combination was relatively
safe and the CR rates were 67% in MRD and 43% in
hematologic relapse.80 Interferon-γ (IFNγ) induced re-
expression of epigenetically silenced MHC class II anti-
gens in relapsed AML clones after allo-HCT.105 One could
hypothesize that treating a patient with IFNγ before
haplo-DLI may result in better tumor alloreactivity,
although it may also increase the risk of GvHD.
Conclusions
• Unmanipulated DLI from a haploidentical donor
appears to be relatively safe and reasonably effective in
patients who relapse after a T-cell replete haplo-HCT.
Patients given haplo-DLI should be enrolled in a clinical
trial whenever possible, as data regarding optimal cell
dose, timing and role of concurrent systemic therapies
with haplo-DLI are limited. Information about the appli-
cation of unmanipulated DLI after T-cell depleted trans-
plantation is limited, which is why dosing should be
managed with caution. 
• The risk of GvHD after unmanipulated DLI in the
haplo-HCT/PTCy setting is comparable to an unmanipu-
lated DLI from an HLA-matched donor.
• Cytoreductive therapy prior to DLI from a haploiden-
tical donor should be considered in patients with a hema-
tologic relapse after haplo-HCT.
• Pre-emptive haplo-DLI may play a role in reducing
disease relapse in patients with persistent MRD or mixed-
donor chimerism after haplo-HCT; however, more stud-
ies are needed.
• Patients with high-risk myeloid malignancies may
benefit from a prophylactic haplo-DLI, which should ide-
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ally be used in the setting of a clinical trial.
• The administration of manipulated DLI after T-cell
depleted or T-cell replete haploidentical transplantation,
such as allodepleted or gene-modified T cells, should only
be performed in the setting of a clinical trial.
• Patients should be monitored closely with frequent
disease-specific MRD testing and donor-chimerism after
DLI administration.
• Mismatched-HLA allele loss was detected in one-
third of leukemia relapses after a haplo-HCT. Such
patients are unlikely to benefit from DLI from the original
donor. A second allo-HCT from a related donor with a
different mismatched haplotype or a mismatched unrelat-
ed donor may be considered if HLA-loss is confirmed.
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